Press
Biogen Idec to Acquire Stromedix
WESTON and CAMBRIDGE, Mass., February 14, 2012 – Biogen Idec (NASDAQ: BIIB) and Stromedix, Inc. today announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc., a privately held biotechnology company focused on innovative therapies for fibrosis and organ failure. Under the terms of the agreement, Biogen Idec will make an upfront cash payment of $75 million and additional contingent value payments of up to $487.5 million based on the achievement of certain development and approval milestones across multiple indications.
Celgene to Acquire Avila Therapeutics
SUMMIT,NJ and BEDFORD, MA – January 26, 2012 – Celgene Corporation (NASDAQ:CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.
Mindspeed Technologies to Acquire PicoChip
NEWPORT BEACH, CA — January 5, 2012 – Mindspeed Technologies, Inc. (NASDAQ: MSPD), a leading supplier of semiconductor solutions for network infrastructure applications, today announced that it is has signed a definitive agreement to acquire U.K.-based Picochip Limited, a leading supplier of integrated system-on-chip (SoC) solutions for small cell base stations, for a purchase price of approximately $51.8 million, plus a potential earnout payment of up to $25 million payable in the first calendar quarter of 2013.
Atlas Venture and Shire Enter Alliance to Invest in Innovative Early-Stage Rare Disease Therapies
CAMBRIDGE, MASS, December 15, 2011–Atlas Venture has entered into a multi-year collaboration with Shire Human Genetic Therapies (“Shire”) to explore investment opportunities in early-stage rare disease therapeutics.
NEW YORK - August 25, 2011 -Verizon Communications Inc. announced today that it has acquired CloudSwitch, an innovative provider of cloud software technology, in a deal that will simplify the move to the enterprise cloud and help to boost industry adoption. Terms of the deal were not disclosed.
NORTHBROOK, IL. – July 28, 2011 – Horizon Pharma, Inc. (Nasdaq: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 per share. Horizon’s common stock is scheduled to begin trading on The NASDAQ Global Market on July 28, 2011 under the symbol “HZNP.” Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments, if any.
NVIDIA Acquires Baseband and RF Technology Leader Icera
BRISTOL, UK and SANTA CLARA, Calif.—May 9, 2011— NVIDIA announced today that it has agreed to acquire Icera, a leading innovator of top-performing baseband processors for 3G and 4G cellular phones and tablets.
Horizon Pharma Announces FDA Approval of DUEXIS®
NORTHBROOK, Ill. – April 25, 2011
Horizon Pharma, Inc., a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved DUEXIS®, (ibuprofen/famotidine) a novel tablet formulation containing a fixed-dose combination of ibuprofen (800 mg) and famotidine (26.6 mg). The FDA approval was supported by data from the pivotal REDUCE-1 and REDUCE-2 studies, which showed patients taking DUEXIS experienced significantly fewer upper gastrointestinal ulcers compared to patients receiving ibuprofen alone.
SciClone Acquires NovaMed Pharmaceuticals
FOSTER CITY, CA — April 19, 2011
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (“Company”) today announced that it has acquired NovaMed Pharmaceuticals Inc., (“NovaMed”) a China-based specialty pharmaceutical company. The acquisition brings additional broad sales and marketing, as well as regulatory and extensive business capabilities and pharmaceutical assets in the regulatory approval stage to its growing and profitable China-focused specialty pharmaceutical business. SciClone believes this acquisition will further position it as a leader in the rapidly expanding pharmaceutical industry in China.
RSS
